Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology Appraisal.
Thielen FW, Büyükkaramikli NC, Riemsma R, Fayter D, Armstrong N, Wei CY, Huertas Carrera V, Misso K, Worthy G, Kleijnen J, Corro Ramos I. Thielen FW, et al. Among authors: fayter d. Pharmacoeconomics. 2019 Aug;37(8):975-984. doi: 10.1007/s40273-018-0740-4. Pharmacoeconomics. 2019. PMID: 30547368 Free PMC article. Review.
Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
Büyükkaramikli NC, de Groot S, Fayter D, Wolff R, Armstrong N, Stirk L, Worthy G, Albuquerque de Almeida F, Kleijnen J, Al MJ. Büyükkaramikli NC, et al. Among authors: fayter d. Pharmacoeconomics. 2018 Feb;36(2):145-159. doi: 10.1007/s40273-017-0581-6. Pharmacoeconomics. 2018. PMID: 29086363 Free PMC article. Review.
Trifluridine-Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ramaekers BLT, Wolff R, van Giessen A, Pouwels X, Fayter D, Lang S, Armstrong N, Worthy G, Duffy S, Kleijnen J, Joore MA. Ramaekers BLT, et al. Among authors: fayter d. Pharmacoeconomics. 2018 Mar;36(3):285-288. doi: 10.1007/s40273-017-0591-4. Pharmacoeconomics. 2018. PMID: 29177842 Free PMC article. Review.
Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Büyükkaramikli NC, de Groot S, Riemsma R, Fayter D, Armstrong N, Portegijs P, Duffy S, Kleijnen J, Al MJ. Büyükkaramikli NC, et al. Among authors: fayter d. Pharmacoeconomics. 2019 Feb;37(2):141-153. doi: 10.1007/s40273-018-0708-4. Pharmacoeconomics. 2019. PMID: 30194622 Free PMC article. Review.
Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Grimm SE, Fayter D, Ramaekers BLT, Petersohn S, Riemsma R, Armstrong N, Pouwels X, Witlox W, Noake C, Worthy G, Kleijnen J, Joore MA. Grimm SE, et al. Among authors: fayter d. Pharmacoeconomics. 2019 Oct;37(10):1195-1207. doi: 10.1007/s40273-019-00792-7. Pharmacoeconomics. 2019. PMID: 30895564 Free PMC article. Review.
30 results